Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, announced a strategic collaboration with Maxymune Therapeutics, a ...
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
-Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, announced results from the landmark myCare-040 clinical ...
Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, published research in mB...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...
23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the official launch of an open-source data platform for the...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that first-line treatment with RYBREVANT® (amivantamab-vmj...
Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 mill...
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...
According to recent statistics, the WHO (World Health Organization) has conducted an assessment of mpox cases in Africa, which showed that, as of 2...
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclus...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
© 2025 Biopharma Boardroom. All Rights Reserved.
